was funded by the Japan Science and Technology (JST), PRESTO (JPMJPR1331), the Japan Society for the Promotion of Science (JSPS), KAKENHI (17K08264), and the PRIME from the Japan Agency for Medical Research and Development (AMED)
Different bottleneck priorities and ratios
This breakthrough offers new hope for millions of patients struggling with diabetes-related kidney complications, providing a more effective treatment option to improve long-term health outcomes
FLEXIBILITY & TRANSPARENCY No hidden fees Cancel anytime 1 month 3 months 6 months 12 months $79 /mo $39 due today for your first month, includes a one-time new-member discount.* INCLUDED CARE Unlimited access to a physician & care team Access to weight loss medications and more In-app care coaching & messaging 24/7 care team support throughout your journey Medication options Compounded Semaglutide + $99/mo Compounded Tirzepatide + $199/mo $39 promotional rate available for new subscribers only
It is not an officially licensed obesity medication in the UK
Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction
